Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

SERGIO DIAZ

Allopathic & Osteopathic Physicians Family Medicine

NPI
1740423474
CMS profile
583844
Location
MCALLEN, TX

General Payments · PY2021–2024

$5,677.02

  • Reported across 197 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$742.93

38 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $742.93 38

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Abbott Laboratories $187.38 3
Novo Nordisk AS $147.50 10
Amgen Inc. $136.51 11
Lilly USA, LLC $77.68 4
Acerta Pharma LLC $70.46 4
Otsuka America Pharmaceutical, Inc. $45.46 2
Astellas Pharma US Inc $33.68 2
ABBVIE INC. $26.20 1
Sumitomo Pharma America, Inc. $18.06 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $788.54 40
PY2022 $2,455.86 66
PY2023 $1,689.69 53
PY2024 $742.93 38

Payment records · PY2024 (38)

Sorted by paying entity, then date · as published by CMS

Program year 2024 202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Abbott Laboratories $157.87 07/18/2024 Food and Beverage Undisputed 01/23/2026 1125232034 CMS
Abbott Laboratories $8.88 08/05/2024 Food and Beverage Undisputed 01/23/2026 1125232042 CMS
Abbott Laboratories $20.63 10/16/2024 Food and Beverage Undisputed 01/23/2026 1125232038 CMS
ABBVIE INC. $26.20 06/20/2024 Food and Beverage Undisputed 01/23/2026 1103638524 CMS
Amgen Inc. $13.34 02/12/2024 Food and Beverage Undisputed 01/23/2026 1117541408 CMS
Amgen Inc. $8.83 02/29/2024 Food and Beverage Undisputed 01/23/2026 1117238899 CMS
Amgen Inc. $28.20 02/29/2024 Food and Beverage Undisputed 01/23/2026 1117541426 CMS
Amgen Inc. $10.30 04/17/2024 Food and Beverage Undisputed 01/23/2026 1117541410 CMS
Amgen Inc. $7.52 05/13/2024 Food and Beverage Undisputed 01/23/2026 1117541412 CMS
Amgen Inc. $16.14 05/23/2024 Food and Beverage Undisputed 01/23/2026 1117541414 CMS
Amgen Inc. $5.75 06/06/2024 Food and Beverage Undisputed 01/23/2026 1117541416 CMS
Amgen Inc. $15.49 07/26/2024 Food and Beverage Undisputed 01/23/2026 1117541418 CMS
Amgen Inc. $10.12 09/11/2024 Food and Beverage Undisputed 01/23/2026 1117541420 CMS
Amgen Inc. $6.34 11/06/2024 Food and Beverage Undisputed 01/23/2026 1117541422 CMS
Amgen Inc. $14.48 11/14/2024 Food and Beverage Undisputed 01/23/2026 1117541424 CMS
Astellas Pharma US Inc $15.72 07/08/2024 Food and Beverage Undisputed 01/23/2026 1139471872 CMS
Astellas Pharma US Inc $17.96 09/13/2024 Food and Beverage Undisputed 01/23/2026 1139530648 CMS
AstraZeneca Pharmaceuticals LP $16.94 01/25/2024 Food and Beverage Undisputed 01/23/2026 1123310820 CMS
AstraZeneca Pharmaceuticals LP $24.60 02/14/2024 Food and Beverage Undisputed 01/23/2026 1123304676 CMS
AstraZeneca Pharmaceuticals LP $13.51 04/17/2024 Food and Beverage Undisputed 01/23/2026 1123311822 CMS
AstraZeneca Pharmaceuticals LP $15.41 04/26/2024 Food and Beverage Undisputed 01/23/2026 1123303026 CMS
Lilly USA, LLC $18.90 02/05/2024 Food and Beverage Undisputed 01/23/2026 1135935520 CMS
Lilly USA, LLC $24.84 09/18/2024 Food and Beverage Undisputed 01/23/2026 1135935522 CMS
Lilly USA, LLC $19.12 10/02/2024 Food and Beverage Undisputed 01/23/2026 1135949322 CMS
Lilly USA, LLC $14.82 10/28/2024 Food and Beverage Undisputed 01/23/2026 1135943538 CMS
Novo Nordisk Inc $24.67 02/01/2024 Food and Beverage Undisputed 01/23/2026 1108572638 CMS
Novo Nordisk Inc $18.54 02/28/2024 Food and Beverage Undisputed 01/23/2026 1108567713 CMS
Novo Nordisk Inc $6.59 02/29/2024 Food and Beverage Undisputed 01/23/2026 1108572608 CMS
Novo Nordisk Inc $10.58 03/11/2024 Food and Beverage Undisputed 01/23/2026 1108566139 CMS
Novo Nordisk Inc $11.29 04/19/2024 Food and Beverage Undisputed 01/23/2026 1108572884 CMS
Novo Nordisk Inc $23.10 06/27/2024 Food and Beverage Undisputed 01/23/2026 1108572832 CMS
Novo Nordisk Inc $9.55 07/18/2024 Food and Beverage Undisputed 01/23/2026 1108570966 CMS
Novo Nordisk Inc $21.05 08/30/2024 Food and Beverage Undisputed 01/23/2026 1108573542 CMS
Novo Nordisk Inc $11.42 09/12/2024 Food and Beverage Undisputed 01/23/2026 1108565553 CMS
Novo Nordisk Inc $10.71 10/17/2024 Food and Beverage Undisputed 01/23/2026 1108567733 CMS
Otsuka America Pharmaceutical, Inc. $22.39 03/21/2024 Food and Beverage Undisputed 01/23/2026 1119059072 CMS
Otsuka America Pharmaceutical, Inc. $23.07 09/05/2024 Food and Beverage Undisputed 01/23/2026 1119059074 CMS
Sumitomo Pharma America, Inc. $18.06 08/07/2024 Food and Beverage Undisputed 01/23/2026 1148955910 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.